The management of multiple sclerosis (MS) has significantly changed from what it was a decade ago. This is in large due to the participation of a large number of MS patients in clinical trials.
A new subcutaneous agent for the management of multiple sclerosis is investigated at UF. This study will provide additional options for patients with aggressive MS that require access to highly effective therapies.
In addition, our newly created MS Center is developing a database of patients suffering from fatigue.
Contact Jennifer Steshyn Jennifer.Steshyn@neurology.ufl.edu for more information.